DelveInsight’s report, “Pulmonary Arterial Hypertension (PAH) Market Insight, Epidemiology, and Market Forecast–2036,” provides a comprehensive analysis of the Pulmonary Arterial Hypertension landscape. The report delivers detailed insights into the disease, including historical and forecasted epidemiology, helping stakeholders understand diagnosed prevalence, patient burden, and market opportunities across key regions.

Additionally, it examines Pulmonary Arterial Hypertension market dynamics, offering a thorough assessment of current treatment practices, unmet needs, and emerging therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and commercialization initiatives.

To know in detail about the Pulmonary Arterial Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here. https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Takeaways from the Pulmonary Arterial Hypertension Market Report

• The Pulmonary Arterial Hypertension market size in the 7MM is projected to increase significantly by 2036, mainly due to the launch of upcoming therapies and expanding diagnosed patient pool.

• The United States accounted for the highest market size among the 7MM in 2025.

• In 2025, the total diagnosed prevalent cases of Pulmonary Arterial Hypertension across the 7MM were approximately 97,000.

• The US accounted for nearly 44,000 diagnosed prevalent cases in 2025.

• EU4 and the UK represented a significant share of the total diagnosed prevalent cases in 2025, while Japan accounted for nearly 23,000 cases.

• Leading companies advancing the pipeline include United Therapeutics, Pfizer, Respira Therapeutics, Gossamer Bio, Liquidia Technologies, and Pharmosa Biopharm.

• Ralinepag is in Phase III development, with topline data projected for release in H1 2026, positioning it as one of the most advanced emerging therapies.

• WINREVAIR (sotatercept) has emerged as a major commercial product and is expected to capture substantial market share by 2036.

• RT234 has shown encouraging Phase IIb clinical progress and could emerge as a potentially transformative therapy for acute symptom relief.

Key Factors Driving the Pulmonary Arterial Hypertension Market

Rising Awareness and Earlier Diagnosis Rates: Increasing awareness of pulmonary vascular disorders, along with broader access to advanced diagnostic testing, is enabling earlier and more accurate diagnosis. Improved recognition among healthcare professionals and patients is expected to expand the identified treatment-eligible population.

High Unmet Need Driving Innovative Therapies: Despite several approved therapies, PAH remains incurable and associated with significant morbidity and mortality. This creates strong opportunities for novel targeted treatments that improve outcomes and address disease progression.

Regulatory Incentives Accelerating Pipeline Development: Supportive regulatory pathways such as Orphan Drug Designation and expedited development programs are encouraging research and development activities. These incentives are helping accelerate clinical advancement, streamline approvals, and attract investment into rare disease pipelines.

Severe Disease Burden Supporting Premium Pricing Potential: The progressive and life-threatening nature of the disease, combined with high treatment costs and long-term management needs, supports premium pricing opportunities for effective novel therapies.

Pulmonary Arterial Hypertension Market Analysis

• Current treatment recommendations weigh multiple factors including WHO functional class, exercise ability, lab indices, hemodynamic and echocardiographic variables to establish severity and guide therapy intensity. Initial treatment choices and subsequent changes are aimed at achieving a low-risk category to improve survival and functional status.

• The current mainstay therapies include PDE5 inhibitors, sGC stimulators, endothelin receptor antagonists, prostacyclin analogs, and agonists. Key marketed products include UPTRAVI, OPSUMIT, TYVASO, ORENITRAM, ADEMPAS, WINREVAIR, and OPSYNVI.

• None of these drugs are curative and side effects remain associated with long-term use. The market has strong demand for therapies with novel mechanisms capable of improving disease progression and quality of life.

Get a Free sample for the Pulmonary Arterial Hypertension Market Forecast, Size & Share Analysis Report: Pulmonary Arterial Hypertension Market Forecast

Pulmonary Arterial Hypertension Competitive Landscape

Key companies such as United Therapeutics, Respira Therapeutics, Gossamer Bio, Liquidia Technologies, and Pharmosa Biopharm are leading the pipeline with differentiated approaches that could transform future treatment options and create meaningful commercial opportunities.

Ralinepag (United Therapeutics): Novel oral selective prostacyclin receptor agonist currently in Phase III ADVANCE OUTCOMES study, with topline data projected in H1 2026.

RT234 (Respira Therapeutics): First-in-class inhaled therapy intended for as-needed use to improve exercise tolerance and provide acute relief from breathlessness and fatigue.

Seralutinib (GB002) (Gossamer Bio): Investigational inhaled therapy targeting proliferative signaling pathways associated with vascular remodeling in PAH.

YUTREPIA (Liquidia Technologies): Inhaled dry powder formulation of treprostinil designed for convenience and improved delivery.

Discover more about therapies set to grab major Pulmonary Arterial Hypertension market share @ Pulmonary Arterial Hypertension Treatment Landscape

Recent Development in the Pulmonary Arterial Hypertension Treatment Landscape:

• In December 2025, Merck received a positive EU CHMP opinion for expanded use of WINREVAIR in adults with PAH.

• In June 2025, United Therapeutics announced completion of enrollment in the Phase III ADVANCE OUTCOMES trial of ralinepag.

• In May 2025, Respira Therapeutics announced presentation of RT234 Phase IIb PAH clinical trial results at ATS 2025.

• In February 2025, United Therapeutics presented TYVASO DPI clinical data at the Pulmonary Vascular Research Institute Annual Congress.

What is Pulmonary Arterial Hypertension?

Pulmonary Arterial Hypertension is a progressive disorder characterized by elevated pressure in the pulmonary arteries and increased pulmonary vascular resistance, eventually leading to right ventricular failure. It can be life-threatening if untreated. PAH belongs to WHO Group 1 pulmonary hypertension and includes idiopathic, heritable, drug-induced, and associated forms.

Pulmonary Arterial Hypertension Epidemiology Segmentation:

The Pulmonary Arterial Hypertension market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Pulmonary Arterial Hypertension

• Age-specific Cases of Pulmonary Arterial Hypertension

• Gender-specific Cases of Pulmonary Arterial Hypertension

• Class-specific Cases of Pulmonary Arterial Hypertension

• Subtype-specific Cases of Pulmonary Arterial Hypertension

• Treated Cases of Pulmonary Arterial Hypertension

Download the report to understand which factors are driving Pulmonary Arterial Hypertension epidemiology trends @ Pulmonary Arterial Hypertension Epidemiology Forecast

Scope of the Pulmonary Arterial Hypertension Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Companies: United Therapeutics, Pfizer, Respira Therapeutics, Gossamer Bio, Liquidia Technologies, Pharmosa Biopharm, and others

• Key Therapies: Ralinepag, PF-07868489, RT234, Seralutinib (GB002), YUTREPIA, L606, WINREVAIR, and others

• Market Dynamics: Drivers and Barriers

• Competitive Intelligence Analysis: SWOT, market entry strategies, reimbursement scenario

• Unmet Needs, KOL Views, Analyst Views, Market Access and Reimbursement

Table of Contents

1. Pulmonary Arterial Hypertension Market Report Introduction

2. Executive Summary for Pulmonary Arterial Hypertension

3. SWOT Analysis of Pulmonary Arterial Hypertension

4. Pulmonary Arterial Hypertension Patient Share (%) Overview at a Glance

5. Pulmonary Arterial Hypertension Market Overview at a Glance

6. Pulmonary Arterial Hypertension Background and Overview

7. Pulmonary Arterial Hypertension Epidemiology and Patient Population

8. Country-Specific Patient Population of Pulmonary Arterial Hypertension

9. Pulmonary Arterial Hypertension Current Treatment and Medical Practices

10. Pulmonary Arterial Hypertension Unmet Needs

11. Pulmonary Arterial Hypertension Emerging Therapies

12. Pulmonary Arterial Hypertension Market Outlook

13. Country-Wise Pulmonary Arterial Hypertension Market Analysis (2022–2036)

14. Pulmonary Arterial Hypertension Market Access and Reimbursement of Therapies

15. Pulmonary Arterial Hypertension Market Drivers

16. Pulmonary Arterial Hypertension Market Barriers

17. Pulmonary Arterial Hypertension Appendix

18. Pulmonary Arterial Hypertension Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/